Adjuvant radiotherapy controversies in localized prostate cancer
DOI:
https://doi.org/10.22517/25395203.25098Keywords:
Radiotherapy, adjuvant, Prostate Cancer, prostatectomy.Abstract
The choice of the most appropriate moment to perform radiotherapy in the treatment of prostate cancer is controversial since it can be performed immediately after prostatectomy or as rescue treatment in case of relapse. In this article, a search for the topic is carried out, the clinical trials with the best evidence are selected and the results are analyzed. Although there is benefit in adjuvant radiotherapy, this result is not found in all patients and it is associated with greater late genitourinary toxicity, therefore, the key is in the selection of treatment according to the specific patient.
Downloads
References
Pisansky TM, Thompson IM, Valicenti RK, D’Amico AV, Selvarajah S. Adjuvant and salvage radiation therapy after prostatectomy: ASTRO/AUA guideline amendment, executive summary 2018. Pract Radiat Oncol. 2019; 9: 208–13.
Thompson I. M., Tangen C. M., Paradelo J., Lucia M. S., Miller G., Troyer D., et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. The Journal of urology. 2019;181(3): 956–962.
Bolla M., van Poppel H., Tombal B., Vekemans K., Da Pozzo L., de Reijke T. M., et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet. 2012; 380(9858): 2018–2027.
Wiegel T., Bartkowiak D., Bottke D., Bronner C., Steiner U., Siegmann A., et al. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. European urology. 2014; 66(2): 243–250.
Tendulkar R. D., Agrawal S., Gao T., Efstathiou J. A., Pisansky T. M., Michalski J. M., et al. Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2016; 34(30): 3648–3654.
Kneebone A., Fraser-Browne C., Duchesne G. M., Fisher R., Frydenberg M., Herschtal A., et al. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial. The Lancet. Oncology. 2020; 21(10): 1331–1340.
Sargos P., Chabaud S., Latorzeff I., Magné N., Benyoucef A., Supiot S., et al. Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. The Lancet. Oncology 2020; 21(10): 1341–1352.
Parker C. C., Clarke N. W., Cook A. D., Kynaston H. G., Petersen P. M., Catton C., et al. Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. Lancet. 2020; 396(10260): 1413–1421.
Tilki D., Chen M., Wu J., Huland H., Graefen M., Wiegel T., et al. Adjuvant Versus Early Salvage Radiation Therapy for Men at High Risk for Recurrence Following Radical Prostatectomy for Prostate Cancer and the Risk of Death. Journal of Clinical Oncology. 2021; 39:20: 2284-2293.
Abdollah F., Karnes R. J., Suardi N., Cozzarini C., Gandaglia G., Fossati N., et al. Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2014; 32(35): 3939–3947.
Jegadeesh N., Liu Y., Zhang C., Zhong J., Cassidy R. J., Gillespie T., et al. The role of adjuvant radiotherapy in pathologically lymph node-positive prostate cancer. Cancer. 2017; 123(3): 512–520.
Abdollah F., Dalela D., Sood A., Montorsi F., Peabody J. O., Mani Menon M., et al. Impact of Adjuvant Radiotherapy in Node-positive Prostate Cancer Patients: The Importance of Patient Selection. Eur Urol Oncol. 2018; 74(3): 253-256.
Downloads
-
Vistas(Views): 213
- PDF (Español (España)) Descargas(Downloads): 126
- PDF Descargas(Downloads): 30
Published
Versions
- 2023-07-13 (2)
- 2023-06-29 (1)
How to Cite
Issue
Section
License
Cesión de derechos y tratamiento de datos
La aceptación de un artículo para su publicación en la Revista Médica de Risaralda implica la cesión de los derechos de impresión y reproducción, por cualquier forma y medio, del autor a favor de Facultad de Ciencias de la Salud de la Universidad Tecnológica de Pereira. 1995-2018. Todos los derechos reservados ®
por parte de los autores para obtener el permiso de reproducción de sus contribuciones. La reproducción total o parcial de los trabajos aparecidos en la Revista Médica de Risaralda, debe hacerse citando la procedencia, en caso contrario, se viola los derechos reservados.
Asimismo, se entiende que los conceptos y opiniones expresados en cada trabajo son de la exclusiva responsabilidad del autor, sin responsabilizarse ni solidarizarse, necesariamente, ni la redacción, ni la editorial.
Es responsabilidad de los autores poder proporcionar a los lectores interesados copias de los datos en bruto, manuales de procedimiento, puntuaciones y, en general, material experimental relevante.
Asimismo, la Dirección de la revista garantiza el adecuado tratamiento de los datos de carácter personal